KYMR Kymera Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 5, 2026
$107,39
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$55,2652-Wochen-Tief
$130,0552-Wochen-Hoch
Marktkapitalisierung (MRQ)
$8.89B
P/E (TTM)
-33.0
EPS (TTM)
$-3.25
Umsatz (TTM)
$105M
Ihre Abzeichen
52W-Spanne
$55–$130
Analystenbewertung
BUY
Kursziel
$139
P/E
-33.0
ROE
-24.2%
Nettogewinnmarge
-285.3%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
KYMR Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$107.39
Marktkapitalisierung (MRQ)
$8.89B
P/E (TTM)
-33.0
EPS (TTM)
$-3.25
Umsatz (TTM)
$105M
ROE (TTM)
-24.2%
52W-Spanne
$55–$130
KYMR Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Über Kymera Therapeutics, Inc. - Common Stock Unternehmensübersicht von Wikipedia
SektorHealthcare
BrancheBiotechnology
Mitarbeiter273
LandUS
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$39M2019-12-31 → 2025-12-31
EPS$-3.692020-12-31 → 2025-12-31
Freier Cashflow$-234M2020-12-31 → 2025-12-31
Nettogewinnmarge-285.3%2020-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | KYMR | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -33.05-Jahres-Durchschnitt ≈-16.8 | ≈-16.8 | · | · | |
| P/S (TTM) | 84.75-Jahres-Durchschnitt ≈72.8 | ≈72.8 | 28.1 | Überbewertet | |
| K/B (MRQ) | 5.95-Jahres-Durchschnitt ≈4.3 | ≈4.3 | 8.1 | Unterbewertet | |
| Kurs / FCF (TTM) | -37.45-Jahres-Durchschnitt ≈-18.4 | ≈-18.4 | · | · | |
| Kurs / Cashflow (TTM) | -37.65-Jahres-Durchschnitt ≈-18.7 | ≈-18.7 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 5.55-Jahres-Durchschnitt ≈4.3 | ≈4.3 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | KYMR | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Betriebsgewinnmarge (TTM) | -333.5%5-Jahres-Durchschnitt ≈-428.0% | ≈-428.0% | -38.2% | Schwach | |
| EBITDA-Marge (TTM) | -325.7%5-Jahres-Durchschnitt ≈-417.8% | ≈-417.8% | -38.2% | Schwach | |
| Pretax Margin (Vorgewinnmarge) | -794.0% | · | 4.3% | Schwach | |
| Nettogewinnmarge (TTM) | -285.3%5-Jahres-Durchschnitt ≈-385.0% | ≈-385.0% | -42.8% | Schwach | |
| ROA (TTM) | -21.6%5-Jahres-Durchschnitt ≈-24.1% | ≈-24.1% | -20.7% | Im Einklang | |
| ROE (TTM) | -24.2%5-Jahres-Durchschnitt ≈-27.9% | ≈-27.9% | -22.4% | Im Einklang | |
| ROIC | -22.1% | · | -19.6% | Im Einklang |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | KYMR | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 10.35-Jahres-Durchschnitt ≈6.7 | ≈6.7 | 8.1 | Starke Liquidität | |
| Quick Ratio | 4.35-Jahres-Durchschnitt ≈1.8 | ≈1.8 | 5.0 | Geringe Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | KYMR | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | -16.7%5-Jahres-Durchschnitt ≈17.9% | ≈17.9% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | -5.7%5-Jahres-Durchschnitt ≈4.3% | ≈4.3% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 2.9% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | KYMR | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.05-Jahres-Durchschnitt ≈0.1 | ≈0.1 | 0.1 | Schwach | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$143.6K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-0.16%
Nächster Bericht
Nov 02, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 10, 2026 | $-0.62 | $-0.73 | 14.8% |
| 31. März 2026 | $-0.71 | $-0.90 | 21.0% | |
| 31. Dezember 2025 | $-0.97 | $-0.81 | -19.4% | |
| 30. September 2025 | $-0.94 | $-0.82 | -14.6% | |
| 30. Juni 2025 | $-0.95 | $-0.83 | -15.0% | |
| 31. März 2025 | $-0.82 | $-0.93 | 12.3% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39M | $47M | $79M | $47M | $73M | $34M | $3M | |
| Cost of Revenue | $39M | $47M | $79M | $47M | · | · | · | |
| R&D Expense | $317M | $240M | $189M | $164M | $137M | $62M | $37M | |
| SG&A Expense | $68M | $64M | $55M | $44M | $36M | $18M | $8M | |
| Operating Expenses | $389M | $309M | $244M | $208M | $173M | $80M | $45M | |
| Operating Income | $-349M | $-262M | $-166M | $-161M | $-101M | $-46M | $-42M | |
| Other Non-op | $38M | $38M | $19M | $6M | $313.0K | $711.0K | $959.0K | |
| Pretax Income | $-311M | · | · | · | · | · | · | |
| Income Tax | $0 | · | · | $0 | $0 | $0 | $0 | |
| Net Income | $-311M | $-224M | $-147M | $-155M | $-100M | $-46M | $-41M | |
| EPS (Basic) | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-3.15 | · | |
| EPS (Diluted) | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-3.15 | · | |
| Shares (Basic) | 84,490,585 | 75,043,991 | 58,365,499 | 53,933,229 | 47,989,023 | 17,349,582 | · | |
| Shares (Diluted) | 84,490,585 | 75,043,991 | 58,365,499 | 53,933,229 | 47,989,023 | 17,349,582 | · | |
| EBITDA | $-341M | $-254M | $-162M | $-158M | $-98M | $-45M | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $357M | $120M | $110M | $68M | $48M | $31M | $76M | |
| Receivables | $0 | $0 | $15M | $0 | · | · | · | |
| Prepaid Expense | $23M | $22M | $12M | $10M | $9M | $5M | $888.0K | |
| Current Assets | $871M | $510M | $405M | $419M | $451M | $302M | $93M | |
| PP&E (Net) | $43M | $50M | $48M | $13M | $12M | $11M | $4M | |
| PP&E (Gross) | $65M | $67M | $59M | $20M | $16M | $13M | $5M | |
| Accum. Depreciation | $22M | $16M | $10M | $7M | $4M | $2M | $1M | |
| Other Non-current Assets | $9M | $2M | $2M | $3M | $2M | $30.0K | $2M | |
| Total Assets | $1.74B | $978M | $576M | $603M | $606M | $487M | $117M | |
| Accounts Payable | $4M | $6M | $7M | $4M | $4M | $4M | $3M | |
| Accrued Liabilities | $42M | $35M | $34M | $28M | $23M | $10M | $5M | |
| Current Liabilities | $83M | $68M | $86M | $71M | $93M | $111M | $35M | |
| Capital Leases | $67M | $72M | $77M | $12M | $13M | $14M | $17M | |
| Other Non-current Liabilities | · | $0 | $0 | $248.0K | $66.0K | $100.0K | · | |
| Total Liabilities | $163M | $142M | $181M | $113M | $146M | $203M | $82M | |
| Common Stock | $8.0K | $7.0K | $6.0K | $6.0K | $5.0K | $4.0K | · | |
| Retained Earnings | $-1.07B | $-755M | $-531M | $-384M | $-229M | $-129M | $-76M | |
| AOCI | $2M | $-1M | $-552.0K | $-5M | $-660.0K | $-128.0K | $6.0K | |
| Stockholders' Equity | $1.58B | $836M | $395M | $490M | $460M | $284M | $-74M | |
| Liabilities + Equity | $1.74B | $978M | $576M | $603M | $606M | $487M | $117M | |
| Shares Outstanding | 81,323,532 | 64,890,193 | 55,585,305 | 55,039,380 | 51,536,181 | 44,482,186 | 1,929,516 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $8M | $7M | $4M | $3M | $2M | $2M | $825.0K | |
| Stock-based Comp | $60M | $55M | $43M | $35M | $25M | $5M | $1M | |
| Other Non-cash | $10M | $-33M | $-3M | $-37M | $-56M | $127M | · | |
| Operating Cash Flow | $-233M | $-195M | $-103M | $-153M | $-129M | $88M | $18M | |
| CapEx | $1M | $13M | $34M | $3M | $2M | $9M | $532.0K | |
| Investing Cash Flow | $-521M | $-404M | $140M | $21M | $-100M | $-423M | $-16M | |
| Financing Cash Flow | $991M | $609M | $4M | $153M | $250M | $289M | $35M | |
| Net Change in Cash | $237M | $10M | $41M | $20M | $21M | $-45M | $36M | |
| Free Cash Flow | $-234M | $-207M | $-137M | $-156M | $-131M | $79M | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -891.1% | -555.8% | -210.6% | -344.4% | -138.0% | -136.1% | · | |
| Net Margin | -794.0% | -475.6% | -187.0% | -330.6% | -137.6% | -134.0% | · | |
| Pretax Margin | -794.0% | · | · | · | · | · | · | |
| EBITDA Margin | -869.9% | -540.2% | -206.1% | -338.0% | -134.7% | -130.9% | · | |
| ROA | -22.9% | -28.8% | -24.9% | -25.6% | -18.3% | -15.1% | · | |
| ROE | -24.4% | -25.9% | -37.2% | -30.9% | -21.3% | -15.8% | · | |
| ROIC | -22.1% | · | · | · | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.5 | 7.5 | 4.7 | 5.9 | 4.9 | 2.7 | · | |
| Quick Ratio | 4.3 | 1.8 | 1.5 | 1.0 | 0.5 | 0.3 | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | · | |
| Receivables Turnover | · | 6.3 | 10.5 | · | · | · | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $19.42 | $12.88 | · | $8.91 | $8.92 | $6.38 | · | |
| Revenue / Share | $0.46 | $0.63 | $1.35 | $0.87 | · | · | · | |
| Cash Flow / Share | $-2.76 | $-2.59 | $-1.76 | $-2.84 | · | · | · | |
| Cash / Share | $4.39 | $1.85 | · | $1.24 | $0.93 | $0.70 | · | |
| EPS (TTM) | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-3.15 | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -16.7% | -40.1% | 67.8% | -35.7% | 114.0% | · | · | |
| Revenue CAGR 3Y | -5.7% | -13.5% | 32.2% | · | · | · | · | |
| Revenue CAGR 5Y | 2.9% | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $39M | $47M | $79M | $47M | $73M | $34M | · | |
| Net Income TTM | $-311M | $-224M | $-147M | $-155M | $-100M | $-46M | · | |
| Market Cap | $6.33B | $2.61B | · | $1.37B | $3.27B | $2.76B | · | |
| P/E | -21.1 | -13.5 | -10.1 | -8.7 | -30.4 | -19.7 | · | |
| P/S | 161.4 | 55.5 | · | 29.3 | 44.9 | 81.0 | · | |
| P/B | 4.0 | 3.1 | · | 2.8 | 7.1 | 9.7 | · | |
| P / Tangible Book | 4.0 | 3.1 | · | 2.8 | 7.1 | 9.7 | · | |
| P / Cash Flow | -27.2 | -13.4 | · | -9.0 | -25.4 | 31.3 | · | |
| P / FCF | -27.0 | -12.6 | · | -8.8 | -25.1 | 34.9 | · | |
| Earnings Yield | -4.7% | -7.4% | -9.9% | -11.5% | -3.3% | -5.1% | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65M | $34M | $3M | $3M | $11M | $22M | $7M | $4M | $26M | $10M | $48M | $5M | $17M | $9M | $16M | $10M | |
| Cost of Revenue | $65M | $34M | $3M | $3M | $11M | $22M | $7M | $4M | $26M | $10M | · | · | · | · | · | · | |
| R&D Expense | $119M | $98M | $84M | $74M | $78M | $80M | $72M | $60M | $59M | $49M | $53M | $48M | $46M | $42M | $43M | $44M | |
| SG&A Expense | $21M | $20M | $17M | $17M | $18M | $16M | $16M | $15M | $17M | $14M | $14M | $14M | $14M | $13M | $12M | $11M | |
| Operating Expenses | $141M | $119M | $101M | $95M | $96M | $97M | $88M | $76M | $77M | $68M | $67M | $62M | $60M | $55M | $55M | $54M | |
| Operating Income | $-76M | $-84M | $-98M | $-93M | $-85M | $-74M | $-81M | $-72M | $-51M | $-58M | $-19M | $-58M | $-43M | $-45M | $-39M | $-45M | |
| Other Non-op | $14M | $15M | $11M | $10M | $8M | $9M | $10M | $10M | $9M | $9M | $5M | $5M | $5M | $4M | $4M | $2M | |
| Income Tax | · | · | · | · | · | · | · | · | · | · | · | $100.0K | $100.0K | $0 | · | $0 | |
| Net Income | $-61M | $-69M | $-87M | $-82M | $-77M | $-66M | $-71M | $-62M | $-42M | $-49M | $-14M | $-53M | $-39M | $-41M | $-35M | $-43M | |
| EPS (Basic) | $-0.62 | $-0.71 | $-0.98 | $-0.94 | $-0.95 | $-0.82 | $-0.89 | $-0.82 | $-0.58 | $-0.69 | $-0.25 | $-0.90 | $-0.67 | $-0.70 | $-0.59 | $-0.79 | |
| EPS (Diluted) | $-0.62 | $-0.71 | $-0.98 | $-0.94 | $-0.95 | $-0.82 | $-0.89 | $-0.82 | $-0.58 | $-0.69 | $-0.25 | $-0.90 | $-0.67 | $-0.70 | $-0.59 | $-0.79 | |
| Shares (Basic) | 98,177,158 | 97,534,269 | · | 87,300,286 | 80,449,405 | 80,146,531 | · | 76,125,975 | 73,059,398 | 70,770,320 | · | 58,421,859 | 58,326,963 | 58,187,038 | · | 54,535,514 | |
| Shares (Diluted) | 98,177,158 | 97,534,269 | · | 87,300,286 | 80,449,405 | 80,146,531 | · | 76,125,975 | 73,059,398 | 70,770,320 | · | 58,421,859 | 58,326,963 | 58,187,038 | · | 54,535,514 | |
| EBITDA | $-76M | $-82M | · | $-93M | $-85M | $-72M | · | $-72M | $-51M | $-56M | · | $-58M | $-43M | $-44M | · | $-45M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $124M | $144M | $357M | $113M | $336M | $90M | $120M | $111M | $68M | $94M | $110M | $81M | $52M | $50M | $68M | $156M | |
| Receivables | $20M | · | · | · | $40M | · | · | $0 | $0 | $0 | · | · | · | · | · | · | |
| Prepaid Expense | $26M | $27M | $23M | $23M | $23M | $18M | $22M | $17M | $14M | $15M | · | $14M | $14M | $11M | · | $9M | |
| Current Assets | $737M | $677M | $871M | $528M | $728M | $501M | $510M | $569M | $525M | $537M | · | $376M | $385M | $412M | · | $494M | |
| PP&E (Net) | $40M | $42M | $43M | $45M | $49M | $49M | $50M | $51M | $52M | $49M | · | $36M | $27M | $17M | · | $13M | |
| PP&E (Gross) | $66M | $66M | $65M | $67M | $69M | $67M | $67M | $65M | $64M | $60M | · | $46M | $36M | $25M | · | $19M | |
| Accum. Depreciation | $26M | $24M | $22M | $22M | $20M | $18M | $16M | $14M | $12M | $11M | · | $10M | $9M | $8M | · | $6M | |
| Other Non-current Assets | $7M | $8M | $9M | $7M | $5M | $3M | $2M | $0 | $2M | $2M | · | $3M | $3M | $3M | · | $3M | |
| Total Assets | $1.65B | $1.67B | $1.74B | $1.10B | $1.13B | $918M | $978M | $1.03B | $826M | $868M | · | $552M | $582M | $614M | · | $638M | |
| Accounts Payable | $9M | $13M | $4M | $6M | $6M | $10M | $6M | $6M | $7M | $7M | · | $5M | $4M | $6M | · | $6M | |
| Accrued Liabilities | $48M | $35M | $42M | $29M | $28M | $23M | $35M | $27M | $24M | $16M | · | $26M | $22M | $19M | · | $25M | |
| Current Liabilities | $71M | $63M | $83M | $72M | $88M | $59M | $68M | $67M | $62M | $56M | · | $63M | $55M | $62M | · | $91M | |
| Capital Leases | $64M | $66M | $67M | $68M | $70M | $71M | $72M | $74M | $75M | $76M | · | $77M | $71M | $64M | · | $12M | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | · | · | · | · | $8.0K | $230.0K | $237.0K | · | $256.0K | |
| Total Liabilities | $136M | $129M | $163M | $156M | $160M | $132M | $142M | $142M | $141M | $157M | · | $157M | $147M | $152M | · | $126M | |
| Common Stock | $8.0K | $8.0K | $8.0K | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K | $6.0K | $6.0K | · | $6.0K | $6.0K | $6.0K | · | $6.0K | |
| Retained Earnings | $-1.20B | $-1.14B | $-1.07B | $-979M | $-897M | $-820M | $-755M | $-684M | $-621M | $-579M | · | $-516M | $-464M | $-425M | · | $-349M | |
| AOCI | $-7M | $-4M | $2M | $2M | $279.0K | $-58.0K | $-1M | $2M | $-2M | $-2M | · | $-2M | $-4M | $-3M | · | $-6M | |
| Stockholders' Equity | $1.51B | $1.54B | $1.58B | $946M | $971M | $786M | $836M | $893M | $685M | $711M | $395M | $396M | $435M | $462M | $490M | $513M | |
| Liabilities + Equity | $1.65B | $1.67B | $1.74B | $1.10B | $1.13B | $918M | $978M | $1.03B | $826M | $868M | · | $552M | $582M | $614M | · | $638M | |
| Shares Outstanding | 82,788,253 | 82,182,101 | 81,323,532 | 71,741,174 | 70,557,442 | 65,112,714 | 64,890,193 | 64,748,226 | 61,572,383 | 61,353,146 | · | 55,450,239 | 55,390,259 | 55,276,226 | · | 54,751,429 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $891.0K | $895.0K | $900.0K | $879.0K | $818.0K | $767.0K | |
| Stock-based Comp | $19M | $16M | $14M | $16M | $15M | $14M | $14M | $15M | $14M | $12M | $11M | $12M | $11M | $9M | $9M | $9M | |
| Other Non-cash | · | $-38M | · | · | · | $-30M | · | · | · | $-4M | · | · | · | $-13M | · | · | |
| Operating Cash Flow | $-54M | $-89M | $-67M | $-27M | $-60M | $-79M | $-62M | $-50M | $-43M | $-40M | $8M | $-32M | $-35M | $-44M | $-40M | $-34M | |
| CapEx | $473.0K | $434.0K | $106.0K | $181.0K | $695.0K | $467.0K | $936.0K | $-189.0K | $5M | $7M | $12M | $8M | $11M | $4M | $373.0K | $1M | |
| Investing Cash Flow | $20M | $-143M | $-394M | $-235M | $60M | $49M | $69M | $-158M | $16M | $-331M | $19M | $61M | $36M | $25M | $-50M | $-37M | |
| Financing Cash Flow | $14M | $19M | $705M | $40M | $246M | $258.0K | $3M | $251M | $1M | $354M | $2M | $-206.0K | $1M | $1M | $2M | $150M | |
| Net Change in Cash | $-20M | $-213M | $244M | $-223M | $246M | $-30M | $10M | $43M | $-26M | $-16M | $29M | $29M | $2M | $-18M | $-87M | $79M | |
| Free Cash Flow | · | $-89M | · | · | · | $-80M | · | · | · | $-47M | · | · | · | $-48M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -116.3% | -244.9% | · | -3347.4% | -736.8% | -336.8% | · | -1927.9% | -198.5% | -562.2% | · | -1216.4% | -262.7% | -478.8% | · | -469.9% | |
| Net Margin | -94.2% | -201.5% | · | -2973.0% | -667.6% | -296.8% | · | -1670.3% | -164.0% | -472.0% | · | -1118.2% | -235.0% | -432.4% | · | -450.2% | |
| EBITDA Margin | -116.3% | -239.0% | · | -3347.4% | -736.8% | -327.5% | · | -1927.9% | -198.5% | -548.0% | · | -1216.4% | -262.7% | -469.5% | · | -469.9% | |
| ROA | -4.4% | -5.3% | · | -7.7% | -7.8% | -7.3% | · | -7.9% | -6.0% | -6.6% | · | -8.9% | -7.0% | -7.0% | · | -6.7% | |
| ROE | -4.9% | -5.9% | · | -8.9% | -9.2% | -8.8% | · | -9.7% | -7.5% | -8.3% | · | -11.6% | -9.3% | -9.2% | · | -8.6% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.3 | 10.8 | · | 7.4 | 8.3 | 8.5 | · | 8.5 | 8.5 | 9.6 | · | 5.9 | 7.1 | 6.6 | · | 5.4 | |
| Quick Ratio | 2.0 | 2.3 | · | 1.6 | 4.3 | 1.5 | · | 1.7 | 1.1 | 1.7 | · | 1.3 | 1.0 | 0.8 | · | 1.7 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 2.2 | · | · | · | 0.6 | · | · | · | · | · | · | · | · | · | · | · |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $18.23 | $18.73 | · | $13.19 | $13.77 | $12.07 | · | $13.79 | $11.12 | $11.59 | · | $7.13 | $7.86 | $8.36 | · | $9.37 | |
| Revenue / Share | $0.66 | $0.35 | · | $0.03 | $0.14 | $0.28 | · | $0.05 | $0.35 | $0.15 | · | $0.08 | $0.28 | $0.16 | · | $0.18 | |
| Cash Flow / Share | · | $-0.91 | · | · | · | $-0.99 | · | · | · | $-0.56 | · | · | · | $-0.76 | · | · | |
| Cash / Share | $1.50 | $1.75 | · | $1.57 | $4.76 | $1.38 | · | $1.71 | $1.10 | $1.52 | · | $1.46 | $0.95 | $0.91 | · | $2.84 | |
| EPS (TTM) | $-3.25 | $-3.58 | · | $-3.60 | $-3.48 | $-3.11 | · | $-2.34 | $-2.42 | $-2.51 | · | $-2.86 | $-2.75 | $-2.86 | · | $-2.95 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $105M | $51M | · | $44M | $45M | $59M | · | $88M | $89M | $79M | · | $47M | $52M | $47M | · | $46M | |
| Net Income TTM | $-300M | $-315M | · | $-295M | $-275M | $-241M | · | $-167M | $-158M | $-155M | · | $-167M | $-158M | $-159M | · | $-154M | |
| Market Cap | $9.49B | $6.84B | · | $4.06B | $3.08B | $1.78B | · | $3.06B | $1.84B | $2.47B | · | $771M | $1.27B | $1.64B | · | $1.19B | |
| P/E | -35.3 | -23.3 | · | -15.7 | -12.5 | -8.8 | · | -20.2 | -12.3 | -16.0 | · | -4.9 | -8.4 | -10.4 | · | -7.4 | |
| P/S | 90.4 | 133.0 | · | 92.8 | 68.9 | 30.3 | · | 35.0 | 20.8 | 31.1 | · | 16.5 | 24.6 | 35.1 | · | 25.9 | |
| P/B | 6.3 | 4.4 | · | 4.3 | 3.2 | 2.3 | · | 3.4 | 2.7 | 3.5 | · | 1.9 | 2.9 | 3.5 | · | 2.3 | |
| P / Tangible Book | 6.3 | 4.4 | · | 4.3 | 3.2 | 2.3 | · | 3.4 | 2.7 | 3.5 | · | 1.9 | 2.9 | 3.5 | · | 2.3 | |
| P / Cash Flow | · | -77.0 | · | · | · | -22.5 | · | · | · | -62.3 | · | · | · | -37.3 | · | · | |
| Earnings Yield | -2.8% | -4.3% | · | -6.4% | -8.0% | -11.4% | · | -4.9% | -8.1% | -6.2% | · | -20.6% | -12.0% | -9.7% | · | -13.6% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $39M | $47M | $79M | $47M | $73M |
| Betriebsgewinnmarge % | -891.1% | -555.8% | -210.6% | -344.4% | -138.0% |
| Nettoergebnis | $-311M | $-224M | $-147M | $-155M | $-100M |
| Verwässerte EPS | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 10.5 | 7.5 | 4.7 | 5.9 | 4.9 |
| Quick Ratio | 4.3 | 1.8 | 1.5 | 1.0 | 0.5 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-234M | $-207M | $-137M | $-156M | $-131M |
Institutionelle Eigentümer (13F) 305 Einreicher · $10.2B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
305
Gehaltener Wert
$10.2B
Neue Positionen
53
Geschlossene Positionen
23
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 53 (+7 vs. Vorquartal) | 23 (-13 vs. Vorquartal) | 101 (+5 vs. Vorquartal) | 80 (+8 vs. Vorquartal) | +431K |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| FMR LLC | $1.416.089.213 | 12.349.256 | 13,95% | Aktien |
| BAKER BROS. ADVISORS LP | $992.725.940 | 8.657.242 | 9,78% | Aktien |
| Avoro Capital Advisors LLC | $857.129.238 | 7.474.747 | 8,44% | Aktien |
| BlackRock, Inc. | $635.066.535 | 5.538.210 | 6,25% | Aktien |
| VANGUARD GROUP INC | $487.685.380 | 6.267.644 | 4,80% | Aktien |
| BVF INC/IL | $444.008.203 | 3.872.052 | 4,37% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $421.415.461 | 3.675.028 | 4,15% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $343.114.771 | 2.992.193 | 3,38% | Aktien |
| Siren, L.L.C. | $336.651.626 | 2.935.830 | 3,32% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $336.255.785 | 2.932.378 | 3,31% | Aktien |
| Atlas Venture Life Science Advisors, LLC | $326.527.526 | 2.847.541 | 3,22% | Aktien |
| STATE STREET CORP | $313.877.705 | 2.737.226 | 3,09% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $208.316.264 | 1.816.331 | 2,05% | Aktien |
| Capital Research Global Investors | $159.262.984 | 1.388.881 | 1,57% | Aktien |
| GOLDMAN SACHS GROUP INC | $136.151.475 | 1.187.333 | 1,34% | Aktien |
| UBS Group AG | $115.561.789 | 1.007.777 | 1,14% | Aktien |
| Driehaus Capital Management LLC | $105.408.448 | 919.233 | 1,04% | Aktien |
| Merck & Co., Inc. | $88.544.161 | 772.165 | 0,87% | Aktien |
| NORGES BANK | $86.833.399 | 757.246 | 0,86% | Aktien |
| FEDERATED HERMES, INC. | $85.933.469 | 749.398 | 0,85% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $85.421.500 | 745.152 | 0,84% | Aktien |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $84.955.104 | 740.866 | 0,84% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $81.750.884 | 981.521 | 0,81% | Aktien |
| Holocene Advisors, LP | $72.996.514 | 636.579 | 0,72% | Aktien |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $72.951.379 | 875.872 | 0,72% | Aktien |
| NORTHERN TRUST CORP | $66.727.276 | 581.907 | 0,66% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $60.744.024 | 529.729 | 0,60% | Aktien |
| FRANKLIN RESOURCES INC | $59.060.783 | 515.050 | 0,58% | Aktien |
| EVENTIDE ASSET MANAGEMENT, LLC | $57.811.287 | 504.210 | 0,57% | Aktien |
| JENNISON ASSOCIATES LLC | $57.676.487 | 502.978 | 0,57% | Aktien |
| Woodline Partners LP | $57.434.534 | 500.868 | 0,57% | Aktien |
| Rock Springs Capital Management LP | $51.963.399 | 453.156 | 0,51% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $51.570.654 | 449.731 | 0,51% | Aktien |
| Boxer Capital Management, LLC | $49.204.897 | 429.100 | 0,48% | Aktien |
| Pictet Asset Management Holding SA | $44.984.008 | 395.540 | 0,44% | Aktien |
| BANK OF AMERICA CORP /DE/ | $43.378.055 | 378.286 | 0,43% | Aktien |
| BRAIDWELL LP | $43.363.951 | 378.163 | 0,43% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $43.100.784 | 375.868 | 0,42% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $42.585.457 | 371.374 | 0,42% | Aktien |
| Clearbridge Investments, LLC | $39.815.871 | 347.221 | 0,39% | Aktien |
| Octagon Capital Advisors LP | $35.547.700 | 310.000 | 0,35% | Aktien |
| Nextech Invest Ltd. | $31.981.004 | 278.896 | 0,31% | Aktien |
| Alyeska Investment Group, L.P. | $31.701.095 | 276.455 | 0,31% | Aktien |
| TD Asset Management Inc | $31.293.443 | 272.900 | 0,31% | Aktien |
| VOYA INVESTMENT MANAGEMENT LLC | $30.951.039 | 269.914 | 0,30% | Aktien |
| TWO SIGMA ADVISERS, LP | $29.085.378 | 373.800 | 0,29% | Aktien |
| Commodore Capital LP | $28.667.500 | 250.000 | 0,28% | Aktien |
| RTW INVESTMENTS, LP | $27.520.800 | 240.000 | 0,27% | Aktien |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $26.799.869 | 233.713 | 0,26% | Aktien |
| GILDER GAGNON HOWE & CO LLC | $26.265.508 | 229.053 | 0,26% | Aktien |
Aktivisten & 5%+-Eigentümer 4 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF PARTNERS L P/IL, BVF INC/IL, LAMPERT MARK N, Hrustanovic Gorjan ×2 Einreichungen | 26. Juni 2026 | 6,30% | Änderung | · | SEC |
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×4 Einreichungen | 11. Dezember 2025 | 10,90% | Änderung | Kapitalstruktur | SEC |
| BIOTECHNOLOGY VALUE FUND, L.P., BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II, L.P., BVF II GP LLC, BIOTECHNOLOGY VALUE TRADING FUND OS, L.P., BVF PARTNERS OS LTD., BVF GP HOLDINGS LLC, BVF PARTNERS L.P., BVF INC., MARK N. LAMPERT, GORJAN HRUSTANOVIC ×5 Einreichungen | 9. Januar 2024 | · | Erste Einreichung | · | SEC |
| Vertex Pharmaceuticals Incorporated ×2 Einreichungen | 5. Juni 2023 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 25 Insider · 10 Führungskräfte · 13 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Nello Mainolfi | Chief Executive Officer | 1. Oktober 2026 M | 666.568 | 0 | 26 | $-36.819.541 |
| Bruce N. Jacobs | Chief Financial Officer | 30. Juni 2026 M | 244.883 | 0 | 15 | $-9.956.105 |
| Jeremy G Chadwick | Chief Operating Officer | 27. Mai 2026 S | 44.018 | 0 | 29 | $-15.599.618 |
| Brian Adams | Chief Legal Officer | 4. September 2026 S | 50.254 | 0 | 3 | $-744.297 |
| Terence Rooney | Chief Medical Officer | 27. Juli 2026 A | 38.000 | 0 | 0 | $0 |
| Noah Goodman | Chief Business Officer | 1. Juli 2026 S | 47.179 | 0 | 9 | $-2.223.845 |
| Jared Gollob | Chief Medical Officer | 2. März 2026 A | 117.134 | 0 | 18 | $-9.134.491 |
| Ellen Chiniara | Chief Legal Officer | 3. März 2025 A | 80.085 | 0 | 0 | $0 |
| Elaine Caughey | Chief Business Officer | 1. März 2023 A | 18.986 | 0 | 0 | $0 |
| Richard Chesworth | Chief Scientific Officer | 27. August 2021 M | 0 | 0 | 0 | $0 |
| Bruce Booth | Direktor | 29. Juni 2026 S | 462.856 | 0 | 160 | $-226.031.370 |
| Hrustanovic Gorjan | Direktor | 24. Juni 2026 A | · | 0 | 0 | $0 |
| Elena Ridloff | Direktor | 24. Juni 2026 A | 0 | 0 | 4 | $-1.285.644 |
| Pamela Esposito | Direktor | 24. Juni 2026 A | 1.000 | 0 | 12 | $-3.054.174 |
| Jeffrey W. Albers | Direktor | 24. Juni 2026 A | 0 | 0 | 3 | $-744.757 |
| Victor Sandor | Direktor | 24. Juni 2026 A | · | 0 | 0 | $0 |
| John Maraganore | Direktor | 24. Juni 2026 A | · | 0 | 0 | $0 |
| Leigh Morgan | Direktor | 18. Juni 2024 A | · | 0 | 0 | $0 |
| Joanna Horobin | Direktor | 7. Juni 2024 M | 0 | 0 | 0 | $0 |
| Donald William Nicholson | Direktor | 15. Juni 2022 A | · | 0 | 0 | $0 |
| Steven Edward Hall | Direktor | 25. August 2020 C | 2.192.249 | 0 | 0 | $0 |
| Andrew Hedin | Direktor | 20. August 2020 A | · | 0 | 0 | $0 |
| Atlas Venture Fund X, L.P. | 10%-Eigentümer | 18. Mai 2021 J | 5.763.012 | 0 | 0 | $0 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10%-Eigentümer | 25. August 2020 C | 959.211 | 0 | 0 | $0 |
| Alexandria Venture Investments, LLC | 10%-Eigentümer | 25. August 2020 C | 467.932 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 48 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| HAPS · Harbor ETF Trust | 2,21% | 36.388 NS | 31. Juli 2026 | N-PORT |
| GURU · Global X Funds | 1,41% | 8.375 NS | 31. Juli 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,90% | 43.133 NS | 31. Juli 2026 | N-PORT |
| BBC · ETFis Series Trust I | 0,80% | 3.605 NS | 31. Juli 2026 | N-PORT |
| IBB · iShares Trust | 0,62% | 543.907 SH | 11. September 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,61% | 5.875 SH | 1. Oktober 2026 | Täglich |
| ESSC · Strategy Shares | 0,44% | 1.522 NS | 31. Juli 2026 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,43% | 24.014 NS | 31. Juli 2026 | N-PORT |
| IWO · iShares Trust | 0,40% | 487.324 SH | 11. September 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,35% | 55.351 SH | 19. August 2026 | Täglich |
| PWS · Pacer Funds Trust | 0,25% | 589 NS | 31. Juli 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,25% | 2.092 NS | 31. Juli 2026 | N-PORT |
| IWM · iShares Trust | 0,24% | 1.600.729 SH | 11. September 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,22% | 360.394 SH | 19. August 2026 | Täglich |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,22% | 14.574 NS | 31. Juli 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,21% | 871.540 SH | 19. August 2026 | Täglich |
| RSSL · Global X Funds | 0,21% | 29.987 NS | 31. Juli 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,19% | 32.324 SH | 19. August 2026 | Täglich |
| FFSM · FIDELITY COVINGTON TRUST | 0,18% | 25.352 NS | 31. Juli 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,14% | 17.965 NS | 31. Juli 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,13% | 7.208 NS | 31. Juli 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,10% | 152.728 NS | 31. Juli 2026 | N-PORT |
| ISCG · iShares Trust | 0,10% | 8.361 SH | 11. September 2026 | Täglich |
| ESML · iShares Trust | 0,09% | 22.280 SH | 11. September 2026 | Täglich |
| VB · VANGUARD INDEX FUNDS | 0,09% | 1.509.269 SH | 19. August 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,08% | 20.141 SH | 1. Oktober 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,08% | 726.357 SH | 19. August 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,08% | 9.461 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,08% | 134.854 SH | 19. August 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,07% | 21.341 NS | 31. Juli 2026 | N-PORT |
| WSML · iShares Trust | 0,06% | 3.284 SH | 11. September 2026 | Täglich |
| FBCG · FIDELITY COVINGTON TRUST | 0,05% | 31.560 NS | 31. Juli 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,02% | 113.415 NS | 31. Juli 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,02% | 5.280 NS | 31. Juli 2026 | N-PORT |
| TILT · FlexShares Trust | 0,01% | 3.058 NS | 31. Juli 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,01% | 15.117 NS | 31. Juli 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,01% | 2.447 NS | 31. Juli 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,01% | 2.089.726 SH | 19. August 2026 | Täglich |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 49.584 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 5.163 SH | 19. August 2026 | Täglich |
| ITOT · iShares Trust | 0,01% | 81.928 SH | 11. September 2026 | Täglich |
| IWV · iShares Trust | 0,01% | 17.103 SH | 11. September 2026 | Täglich |
| ESGV · VANGUARD WORLD FUND | 0,01% | 13.837 SH | 19. August 2026 | Täglich |
| DFUS · Dimensional ETF Trust | 0,00% | 9.292 NS | 31. Juli 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,00% | 151 NS | 31. Juli 2026 | N-PORT |
| IWN · iShares Trust | · | 102.204 SH | 11. September 2026 | Täglich |
| ISCB · iShares Trust | · | 2.398 SH | 11. September 2026 | Täglich |
| ISCV · iShares Trust | · | 6.014 SH | 11. September 2026 | Täglich |
KYMR Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 30 Analysten
KAUF
Median-Ziel
$135.50
+26,2%
10 33,3%
Starker Kauf
16 53,3%
Kauf
4 13,3%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
22 Analysten · 2026-09-27Mittelwert-Ziel $138.64 +29,1%
← Unter allen Zielen
Aktueller Preis $107.39
Tief$111.00
Mittelwert$138.64
Hoch$180.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | · |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | · |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | · |
| PTGX | $5.47B | -42.6 | -89.4% | -282.8% | -20.3% | · |
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | · |
| PCVX | $6.05B | -8.2 | · | · | -26.6% | · |
| TGTX | $4.63B | 10.8 | 87.3% | 72.6% | 96.7% | · |
| PRAX | $7.43B | -21.9 | 249.5% | · | -47.3% | · |
| SYRE | $2.56B | 10.1 | -62.0% | · | -26.5% | · |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 5, 2026